Global Retinal Disorder Treatment Market, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
-
15953
-
May 2023
-
184
-
-
This report was compiled by Correspondence Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
Global Retinal Disorder Treatment Market is an upcoming market research report at MarketResearch.biz. In this report, important data and information on the global location intelligence market, such as details of key players, potential revenue growth opportunities, market restraints, trends, recent developments, revenue details, competitive landscapes, and drivers are included.
Conclusions and research findings are verified by industry experts before being included in this report. Moreover, extensive primary and secondary research efforts are conducted to ensure the accuracy of research findings. The report is segmented on the basis of type, dosage form, distribution channel, and region/country.
Global Retinal Disorder Treatment Market Overview
The retina is a layer of nerve tissues that lines the back of the eye and is located near the optic nerve. It receives light, which is then converted into neural signals that are sent to the brain for visual recognition. The Macula, which is the central part of the retina, is responsible for central vision. Peripheral vision is made possible by tissue outside the macula.
There are different types of retinal diseases. Some affect only the macula, such as macular pucker (epiretinal membrane), age-related macular degeneration, or macular hole. Whereas disorders such as diabetic retinopathy and retinal detachment affect the entire retina.
The process of treatment of retinal diseases includes the administration of eye drops and surgical procedures such as vitreoretinal surgery, laser therapy, and intraocular injection.
Dynamics
A key factor that is expected to drive market growth is increased funding by different regulatory bodies to conduct ocular bodies research. In addition, the increasing incidence of retinal disorders across the globe, and the need for more affordable and effective treatment options are projected to drive market growth over the coming years.
According to the National Eye Institute, between 10-14 million people are expected to suffer from diabetic retinopathy in the US from 2030-2050 respectively. Another factor expected to contribute to the growth of the global retinal disorder treatment market is the ever-growing geriatric population. According to World Population Prospects, around one in four and one in eleven people residing in Europe and North America respectively will be aged 65 years and over by 2050.
Other major factors that are expected to drive this market’s growth are the presence of strong pipeline products and the commercialization of novel products. In addition, increasing strategic collaborations and technological advancements are projected to support the growth of the global retinal disorder treatment market over the years to come.
An increasing base of trained professionals that are specialized in the treatment of retinal diseases is expected to result in the availability of easier treatment options to choose from. However, the high cost associated with the treatment of retinal disorders is expected to hamper this market’s growth. Continuous research & development and technological advancements are projected to create growth opportunities for key players operating in the global market over the next ten years.
Global Retinal Disorder Treatment Market Segment Analysis:
By Type:
The macular degeneration segment continues to account for the highest revenue share in the global retinal disorder market in comparison to the other type segments. This can be attributed to the rise in the number of product launches for macular degeneration treatment. In addition, an increase in the number of advertising and awareness campaigns being conducted and funded by governmental as well as non-governmental organizations is resulting in more individuals becoming aware of these diseases as well as the subsequent advancements in eye treatment. These factors are positively contributing to the revenue growth of this segment.
By Dosage Form:
The eye solution segment is expected to continue to account for the majority revenue share over the coming years. This can be attributed to the availability of different eye injections, including EYLEA and Lucentis that are meant for the treatment of retinal disorders. The segment for eye drops is projected to index the fastest revenue growth over the next ten years.
Global Retinal Disorder Treatment Market Regional Analysis:
The retinal disorder treatment market in North America is expected to account for a majority in terms of revenue share over the coming years. This can be attributed to the presence of key players such as ALLERGAN PLC, Novartis AG, and Bausch & Lomb in countries of this region.
Global Retinal Disorder Treatment Market Segmentation:
By Type:
- Macular Degeneration
-
- Dry Macular Degeneration
- Wet Macular Degeneration
- Diabetic Retinopathy
- Others
By Dosage Form:
- Gels
- Eye Solutions
- Capsules & Tablets
- Eye Drops
- Ointments
By Distribution Channel:
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
-
- Santen Pharmaceutical Co. Ltd.
- REGENERON
- Graybug Vision Inc.
- Shire (Takeda Pharmaceuticals)
- Bayer AG
- Genentech Inc.
- Acucela Inc.
- Pfizer Inc.
Our Clients
View Our Licence Options
